uniqure delivers POC for hemophilia B gene therapy
Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Ose Pharma gets clinical milestone for IL7R antagonist
/in News/by Thomas GabrielczykOse Immunotherapeutics has got the first milestone payment within its 272m deal with Servier inked in 2016.
How stroma cells trigger tumour angiogenesis
/in News/by Thomas GabrielczykAnalyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
Jennewein Biotechnologie expands into Chinese market
/in News/by Thomas GabrielczykJennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.
Medicxi put 40m into two Sosei spin off companies
/in News/by Thomas GabrielczykSosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMA greenlights two orphan drugs and two biosimilars
/in News/by Thomas GabrielczykEMAs human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi expands European reach in cell and gene therapy
/in News/by Thomas GabrielczykHitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the […]
Dewpoint Therapeutics kicks off with $60m financing
/in News/by Thomas GabrielczykDewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
IPO: Marinomed sets offer price
/in News/by Thomas GabrielczykMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of 75 per new share.
Novozymes partners with Carbios subsidiary Carbiolice
/in News/by Thomas GabrielczykNovozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.